NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.